TRPM4 channel is involved in regulating epithelial to mesenchymal transition, migration, and invasion of prostate cancer cell lines
Present address: Eduardo A. Sagredo and Ricardo Armisén, Center of Excellence in Precision Medicine Pfizer Chile, Obispo Arturo Espinoza Campos 2526, Macul, Santiago, Chile
Abstract
Transient Receptor Potential Melastatin 4 (TRPM4) is a Ca2+‐activated and voltage‐dependent monovalent cation channel, which depolarizes the plasma cell membrane, thereby modulating Ca2+ influx across Ca2+‐permeable pathways. TRPM4 is involved in different physiological processes such as T cell activation and the migration of endothelial and certain immune cells. Overexpression of this channel has been reported in various types of tumors including prostate cancer. In this study, a significant overexpression of TRPM4 was found only in samples from cancer with a Gleason score higher than 7, which are more likely to spread. To evaluate whether TRPM4 overexpression was related to the spreading capability of tumors, TRPM4 was knockdown by using shRNAs in PC3 prostate cancer cells and the effect on cellular migration and invasion was analyzed. PC3 cells with reduced levels of TRPM4 (shTRPM4) display a decrease of the migration/invasion capability. A reduction in the expression of Snail1, a canonical epithelial to mesenchymal transition (EMT) transcription factor, was also observed. Consistently, these cells showed a significant change in the expression of key EMT markers such as MMP9, E‐cadherin/N‐cadherin, and vimentin, indicating a partial reversion of the EMT process. Whereas, the overexpression of TRPM4 in LnCaP cells resulted in increased levels of Snail1, reduction in the expression of E‐cadherin and increase in their migration potential. This study suggests a new and indirect mechanism of regulation of migration/invasion process by TRPM4 in prostate cancer cells, by inducing the expression of Snail1 gene and consequently, increasing the EMT.
Citing Literature
Number of times cited according to CrossRef: 7
- Dongki Yang, Jaehong Kim, Emerging role of transient receptor potential (TRP) channels in cancer progression, BMB Reports, 10.5483/BMBRep.2020.53.3.016, 53, 3, (125-132), (2020).
- Fujue Wang, Pengqiang Wu, Shuaige Gong, Yingying Chen, Jie Gao, Shuoting Wang, Qianqing Shen, Huan Tao, Fang Hua, ZhenCang Zhou, Zhongqing Zou, Tao Ma, Yongqian Jia, Aberrant TRPM4 expression in MLL-rearranged acute myeloid leukemia and its blockade induces cell cycle arrest via AKT/GLI1/Cyclin D1 pathway, Cellular Signalling, 10.1016/j.cellsig.2020.109643, (109643), (2020).
- José Rivas, Nicolás Díaz, Ian Silva, Danna Morales, Boris Lavanderos, Alhejandra Álvarez, María Paz Saldías, Eduardo Pulgar, Pablo Cruz, Diego Maureira, Guillermo Flores, Alicia Colombo, Constanza Blanco, Héctor R. Contreras, Fabián Jaña, Ivan Gallegos, Miguel L. Concha, Ariela Vergara‐Jaque, Horacio Poblete, Wendy González, Diego Varela, James S. Trimmer, Mónica Cáceres, Oscar Cerda, KCTD5, a novel TRPM4‐regulatory protein required for cell migration as a new predictor for breast cancer prognosis, The FASEB Journal, 10.1096/fj.201901195RRR, 34, 6, (7847-7865), (2020).
- Kah Keng Wong, Faezahtul Arbaeyah Hussain, TRPM4 is overexpressed in breast cancer associated with estrogen response and epithelial-mesenchymal transition gene sets, PLOS ONE, 10.1371/journal.pone.0233884, 15, 6, (e0233884), (2020).
- Sven Kappel, Paulina Stokłosa, Barbara Hauert, Daniela Ross‐Kaschitza, Anna Borgström, Roland Baur, José A. Galván, Inti Zlobec, Christine Peinelt, TRPM4 is highly expressed in human colorectal tumor buds and contributes to proliferation, cell cycle, and invasion of colorectal cancer cells, Molecular Oncology, 10.1002/1878-0261.12566, 13, 11, (2393-2405), (2019).
- Yahui Gao, Ping Liao, TRPM4 channel and cancer, Cancer Letters, 10.1016/j.canlet.2019.04.012, (2019).
- Li Liu, Jiajing Lin, Hongying He, Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer, Frontiers in Genetics, 10.3389/fgene.2019.00373, 10, (2019).
